The success of the tumor immunotherapy: neutrophils from bench to beside
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Янв. 24, 2025
The
present
immune
therapy
was
focused
on
the
checkpoint
blockade
or
Chimeric
Antigen
Receptor
T-Cell
Immunotherapy
(CART)
transfer,
but
how
to
activate
innate
system
antitumor
still
lags
out.
Neutrophils
are
most
abundant
circulating
leukocytes
in
human,
and
heterogeneous
neutrophils
have
been
increasingly
recognized
as
important
players
tumor
progression.
They
play
double
“edge-sward”
by
either
supporting
suppressing
growth,
including
driving
angiogenesis,
extracellular
matrix
remodeling
promote
participating
adaptive
immunity,
killing
cells
directly
inhibit
growth.
complex
role
of
various
tumors
depends
microenvironment
(TME)
they
located,
emerging
evidence
has
suggested
that
may
determine
success
immunotherapy
context
blockade,
training,
drug-loaded
microvesicles
therapy,
which
makes
them
become
an
exciting
target
for
immunotherapy,
with
challenges.
Here,
we
summarize
latest
insights
immunity
discuss
advances
neutrophil-targeted
strategies.
Язык: Английский
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit
Cancer Cell,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
Cytokine‐centered strategies to boost cancer immunotherapy
Molecular Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 7, 2025
Cytokines
have
gained
attention
in
oncology
recent
years,
especially
the
context
of
immunotherapy.
Although
immune
checkpoint
inhibitors
(ICIs)
revolutionized
treatment
cancer,
there
are
still
some
challenges
to
be
faced,
such
as
lack
predictive
biomarkers
well
emergence
resistance
and
their
severe
side
effects.
In
this
Viewpoint,
we
discuss
potential
cytokines,
soluble
mediators
cancer-associated
inflammation,
Indeed,
both
activation
inhibition
cytokines
been
suggested
strategies
overcome
immunotherapy
resistance.
addition,
serum
levels
certain
can
predict
response
immunotherapy,
cytokine
could
also
contribute
prevent
effects
induced
by
ICIs.
Thus,
although
further
research
is
required,
data
support
that
cytokine-based
therapies
an
attractive
therapeutic
strategy
for
cancer
patients
treated
with
near
future.
Язык: Английский
Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(4), С. 1440 - 1440
Опубликована: Фев. 8, 2025
Antibody-based
immune-stimulating
drugs
(ABIs)
represent
a
transformative
frontier
in
cancer
immunotherapy,
designed
to
reshape
the
tumor
microenvironment
and
overcome
immune
suppression.
This
study
highlighted
recent
advances
ABIs,
including
antibody
conjugates
(ISACs),
bispecific
antibodies
(BsAbs),
checkpoint
blockade
enhancers,
with
focus
on
their
mechanisms
of
action,
clinical
advancements,
challenges.
Preclinical
findings
revealed
that
ISACs
effectively
boost
overall
anti-cancer
immunity
by
reprogramming
tumor-associated
macrophages,
enhancing
T
cell
activation,
engaging
other
pathways.
Similarly,
BsAbs
redirect
cells
tumors,
achieving
significant
regression.
Additionally,
artificial
intelligence
(AI)
is
revolutionizing
development
ABIs
optimizing
drug
design,
identifying
novel
targets,
accelerating
preclinical
validation,
enabling
personalized
therapeutic
strategies.
Despite
these
challenges
remain,
resistance
off-target
effects.
Future
research
should
prioritize
next-generation
multifunctional
antibodies,
AI-driven
innovations,
combination
therapies
enhance
efficacy
expand
applications.
Connecting
gaps
could
unlock
full
potential
upgrading
treatment
improving
outcomes
for
patients
refractory
or
resistant
tumors.
Язык: Английский
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
Frontiers in Pharmacology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 21, 2025
Antibody-drug
conjugates
have
emerged
as
a
promising
cancer
treatment,
combining
targeted
delivery
of
cytotoxic
agents
with
the
specificity
monoclonal
antibodies.
Despite
their
potential,
ADCs
face
limitations
such
resistance
and
off-target
effects.
To
enhance
efficacy,
are
increasingly
being
combined
other
therapeutic
strategies,
including
immune
checkpoint
inhibitors,
chemotherapy,
small-molecule
anti-angiogenic
agents,
CAR-T
cell
therapies.
These
combination
therapies
aim
to
overcome
mechanisms,
improve
tumor
targeting,
boost
responses.
Clinical
studies
shown
that
combinations
can
significantly
response
rates
progression-free
survival
across
various
cancers.
This
review
explores
clinical
key
studies,
challenges,
future
perspectives
in
therapy.
Язык: Английский
The Challenging Scenario of Cancer Treatment for People with HIV: Clinical Experience with Immune Checkpoint Inhibitors
Current Oncology,
Год журнала:
2025,
Номер
32(3), С. 164 - 164
Опубликована: Март 13, 2025
Over
the
past
decade,
there
has
been
a
notable
increase
in
utilization
of
immune
checkpoint
inhibitors
cancer
care,
transforming
therapeutic
landscape
for
several
types
solid
tumors.
This
development
not
only
expanded
indications
treatment
but
also
significantly
influenced
management
strategies
and
prognostic
outcomes
specific
subsets
patients.
In
contrast
to
general
population
patients,
individuals
diagnosed
with
both
HIV
encounter
significant
differences
approaches
outcomes.
Consequently,
this
demonstrates
increased
rate
mortality
common
cancer.
Recent
studies
have
reported
insights
into
use
among
patient
group.
However,
data
remain
insufficient,
are
still
recognized
barriers
limitations
regarding
these
agents
Real-world
reports
from
clinical
practice
offer
critical
perspectives,
enabling
sharing
experiences
assisting
navigating
complex
decisions.
report
outlines
two
cases
patients
concurrent
who
were
administered
ICIs
diverse
settings,
highlighting
necessity
cooperation
between
oncologists
specialists
provide
cutting-edge
increasingly
tailored
options.
Язык: Английский
Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial
Vaccines,
Год журнала:
2025,
Номер
13(4), С. 390 - 390
Опубликована: Апрель 5, 2025
Background:
A
previous
phase
I/II
study
demonstrated
potent
and
long-term
immune
responses
in
men
with
prostate
cancer
following
vaccination
a
20mer
synthetic
peptide
(RV001)
derived
from
the
Ras
homolog
gene
family
member
C
protein
(RhoC).
Moreover,
fraction
of
patients
experienced
prostate-specific
antigen
(PSA)
responses,
which
prompted
initiation
II
double-blind
randomized
trial
(NCT04114825).
The
primary
endpoint
was
to
whether
could
postpone
PSA
progression.
Furthermore,
included
an
evaluation
vaccination-induced
in-depth
vitro
studies
RhoC-specific
CD4+
T
cell
responses.
Methods:
Men
non-metastatic
biochemical
recurrence
after
either
radical
prostatectomy
or
radiation
therapy
were
eligible
for
study.
Participants
1:1
subcutaneous
injections
0.1
mg/mL
RV001
emulsified
Montanide
ISA
51,
placebo.
Vaccinations
administered
every
2
weeks
first
six
times,
then
five
times
4
total
treatment
time
30
weeks.
Blood
samples
collected
subset
(n
=
38)
over
course
vaccination,
peripheral
blood
mononuclear
cells
(PBMCs)
isolated
immunological
assessment
vaccine-induced
Experiments
using
PBMCs
healthy
donor
patient
performed
phenotype
function
RV001-specific
cells.
Results:
192
entered
There
no
difference
doubling,
7.5
versus
9.3
months,
initiating
further
therapies,
11.2
17.6
months
control
groups,
respectively.
At
follow-up,
12.9%
arm
had
developed
metastasis
compared
12%
placebo
arm.
No
serious
treatment-related
side
effects
observed,
adverse
events
did
not
differ
between
groups.
Immunological
examinations
that
induced
potent,
long-lasting
capable
proliferation
cytokine
production.
shown
mediate
cytotoxicity
against
RhoC-expressing
line
HLA-class
II-dependent
manner.
Conclusions:
active
RV001V
induction
functionally
capable,
anti
RhoC-CD4+
However,
there
benefit
progression,
second-line
therapies.
Язык: Английский
Neoantigen vaccines: advancing personalized cancer immunotherapy
Exploration of Immunology,
Год журнала:
2025,
Номер
5
Опубликована: Апрель 8, 2025
Neoantigen
vaccines
are
a
promising
strategy
in
cancer
immunotherapy
that
leverage
tumor-specific
mutations
to
elicit
targeted
immune
responses.
Although
they
have
considerable
potential,
development
challenges
related
antigen
prediction
accuracy,
manufacturing
complexity,
and
scalability
remain
key
obstacles
their
widespread
clinical
use.
This
literature
review
was
conducted
using
PubMed,
Scopus,
Web
of
Science,
Google
Scholar
databases
identify
relevant
studies.
Keywords
included
“neoantigen
vaccines,”
“personalized
immunotherapy,”
“tumor
heterogeneity,”
“bioinformatics
pipelines,”
“prediction
algorithms”.
Clinical
trial
data
were
sourced
from
ClinicalTrials.gov,
Trialtrove,
other
publicly
available
registries.
Eligible
studies
peer-reviewed
research
articles,
systematic
reviews,
trials
focusing
on
neoantigen
vaccine
development,
bioinformatic
strategies,
immunotherapy.
Tumor
heterogeneity
clonal
evolution
significantly
impact
efficacy,
necessitating
multi-epitope
targeting
adaptive
design.
Current
algorithms
suffer
high
false-positive
false-negative
rates,
requiring
further
integration
with
multi-omics
machine
learning
enhance
accuracy.
Manufacturing
remains
complex,
time-intensive,
costly,
advancements
standardization
automation.
Combination
therapies,
such
as
checkpoint
inhibitors
adoptive
cell
counteract
the
immunosuppressive
tumor
microenvironment,
improving
treatment
outcomes.
hold
great
potential
for
personalized
therapy
but
require
bioinformatics,
scalability,
immunomodulatory
strategies
efficacy.
Continued
interdisciplinary
collaboration
essential
refining
applications.
Язык: Английский
Exploration of the role of immune cells and cell therapy in hepatocellular carcinoma
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Апрель 16, 2025
Hepatocellular
carcinoma
stands
as
one
of
the
foremost
contributors
to
cancer-associated
fatalities
globally,
and
limitations
traditional
treatment
methods
have
prompted
researchers
explore
new
therapeutic
options.
Recently,
cell
therapy
has
emerged
a
promising
approach
for
HCC,
showing
significant
potential
in
improving
patient
outcomes.
This
review
article
explores
use
covering
different
types,
mechanisms
behind
their
effectiveness,
recent
advancements
clinical
trials,
ongoing
challenges.
aims
provide
insightful
perspectives
future
research
applications
treating
HCC
by
synthesizing
current
knowledge.
Язык: Английский